U.S. markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.64 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.92 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    -1.87 (-2.94%)
     
  • Gold

    1,733.00
    -42.40 (-2.39%)
     
  • Silver

    26.70
    -0.98 (-3.56%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.81%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • GBP/USD

    1.3922
    -0.0091 (-0.65%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.30%)
     
  • BTC-USD

    46,607.82
    +526.10 (+1.14%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical and non-clinical data on BTK inhibitor BRUKINSA™ (zanubrutinib) and clinical data on anti-PD-1 antibody tislelizumab will be presented in an oral presentation and eight posters at the 25th European Hematology Association (EHA) Virtual Congress, taking place on June 11-14, 2020.

Oral Presentation:

Title:

ASPEN: Results of a Phase 3 Randomized Trial Of Zanubrutinib Versus Ibrutinib for Patients with Waldenström Macroglobulinemia (WM)

Abstract #:

S225

Session Title:

Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical

Presenter:

Meletios Dimopoulos, M.D., National and Kapodistrian University of Athens, Greece

Poster Presentations:

Title:

Updated Results of the ASPEN Trial from a Cohort of Patients with MYD88 Wild-Type Waldenström Macroglobulinemia

Abstract #:

EP1180

Session Title:

Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical

Lead Author:

Meletios Dimopoulos, M.D., National and Kapodistrian University of Athens, Greece


Title:

Three-Year Follow-Up of Treatment-Naïve and Previously Treated Patients with Waldenström Macroglobulinemia (WM) Receiving Single Agent Zanubrutinib

Abstract #:

EP1168

Session Title:

Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical

Lead Author:

Stephen Opat, MBBS, Monash University, Australia


Title:

Phase 1/2 Study of Single-Agent Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Abstract #:

EP1165

Session Title:

Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical

Lead Author:

Alessandra Tedeschi, M.D., Niguarda Cancer Center, Italy


Title:

Tislelizumab (BGB-A317) for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study

Abstract #:

EP1268

Session Title:

Aggressive Non-Hodgkin Lymphoma – Clinical

Lead Author:

Huiqiang Huang, M.D., Ph.D., Sun Yat-sen University Cancer Center, China


Title:

Tislelizumab (BGB-A317) for Relapsed/Refractory Peripheral T-Cell Lymphomas: Safety and Efficacy Results from a Phase 2 Study

Abstract #:

EP1235

Session Title:

Aggressive Non-Hodgkin Lymphoma – Clinical

Lead Author:

Pier Luigi Zinzani, M.D., Ph.D., University of Bologna, Italy


Title:

Biomarker Identification in Relapsed/Refractory Non-Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma Treated with Zanubrutinib

Abstract #:

EP1246

Session Title:

Aggressive Non-Hodgkin Lymphoma – Clinical

Lead Author:

Haiyan Yang, M.D., Zhejiang Cancer Hospital, China


Title:

Zanubrutinib (BGB-3111) in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Abstract #:

EP1271

Session Title:

Aggressive Non-Hodgkin Lymphoma – Clinical

Lead Author:

Jianfeng Zhou, M.D., Tongji Medical College, China


Title:

Outcomes of Relapsed/Refractory MCL Patients Treated with Zanubrutinib Monotherapy in the Second Line and in Later Lines: A Pooled Analysis from 2 Studies

Abstract #:

EP1169

Session Title:

Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical

Lead Author:

Keshu Zhou, M.D., Henan Cancer Hospital, China

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,800+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA™ (zanubrutinib) in the United States, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

BeiGene Investor Contact

Craig West
+1 857-302-5189
ir@beigene.com

BeiGene Media Contact

Liza Heapes
+1 857-302-5663
media@beigene.com